Blogs

Roughly 1 in 28 women in India will develop breast cancer in her lifetime — and unlike in the West, Indian women are being diagnosed nearly a decade earlier on average. If you or someone you love has just heard the words “breast cancer,” the first question is almost always the same: why did this happen? The honest answer is that breast cancer is rarely caused by one single factor. It is the result of genetic, hormonal, lifestyle, and environmental influences interacting over years, sometimes decades.

For many families in Mumbai and across India, this uncertainty is one of the hardest parts of a diagnosis. There is no single test that says “this is why,” and searching online often produces conflicting, alarming, or oversimplified answers.

In this guide, you will learn what actually causes breast cancer, the major types and subtypes you may hear from your oncologist — including triple negative and HER2 positive/negative breast cancer — and where Ayurvedic supportive care realistically fits into a patient's journey, without overstating what it can do.

This article has been reviewed for medical accuracy and is written in accordance with Indian advertising and healthcare-claim regulations. Health Reactive India is an ISO and GMP-certified Ayurvedic wellness manufacturer that has supported over 1 lakh cancer patients with immunity-focused supportive care since 1996.

What Actually Causes Breast Cancer?

Breast cancer starts when cells in breast tissue begin to divide and grow abnormally, eventually forming a tumour. This happens because of mutations — changes — in the DNA that normally controls cell growth. Some of these mutations are inherited from a parent; most develop during a person's lifetime due to a combination of biological ageing, hormonal exposure, and external factors.

Breast cancer is caused by genetic mutations that make breast cells grow and divide uncontrollably. It works through damage to genes that normally regulate cell division, such as BRCA1 and BRCA2. Most cases result from a combination of age, hormones, and lifestyle factors rather than a single inherited gene.

Genetic and Family History Factors

Around 5–10% of breast cancers are linked to inherited mutations, most commonly in the BRCA1 and BRCA2 genes. Women with a first-degree relative — mother, sister, or daughter — diagnosed with breast cancer have roughly double the average risk, according to data cited by the American Cancer Society (2024).

Hormonal Factors

Extended exposure to estrogen and progesterone — through early menstruation, late menopause, not having children, or long-term hormone replacement therapy — is associated with higher risk. This is why breast cancer risk generally rises with age, particularly after 45.

Lifestyle and Environmental Factors

Obesity after menopause, physical inactivity, regular alcohol consumption, and long-term exposure to certain environmental chemicals have all been linked to increased risk in population studies. None of these guarantee cancer will develop — they shift probability, not certainty.

What Are the Main Types of Breast Cancer?

Not all breast cancer is the same. Oncologists classify tumours by where they start and by specific biological markers, because this determines which treatments will work best.

The main types of breast cancer are ductal carcinoma, lobular carcinoma, and inflammatory breast cancer, classified by where the tumour originates. Subtypes are further defined by hormone receptor and HER2 status. This classification guides which treatments an oncologist recommends.

Ductal and Lobular Carcinoma

Ductal carcinoma, which begins in the milk ducts, accounts for the majority of cases. Lobular carcinoma begins in the milk-producing lobules and is less common but can be harder to detect on a mammogram.

Inflammatory Breast Cancer

Inflammatory breast cancer (IBC) is a rare but aggressive subtype that often does not present as a distinct lump. Instead, it causes redness, swelling, warmth, and a thickened, pitted skin texture resembling an orange peel. Because it can be mistaken for an infection, diagnosis is sometimes delayed — making awareness of these symptoms especially important.

Triple Negative and HER2 Breast Cancer: What Do They Mean?

Once a biopsy confirms breast cancer, pathology testing checks for three receptors: estrogen (ER), progesterone (PR), and HER2 protein. The combination determines the subtype and the treatment pathway.

Triple negative breast cancer tests negative for estrogen, progesterone, and HER2 receptors. HER2 positive breast cancer has excess HER2 protein driving faster cell growth. HER2 negative cancers lack this protein and are typically treated based on hormone receptor status instead.

Triple Negative Breast Cancer (TNBC)

TNBC lacks all three receptors, which means hormone-blocking and HER2-targeted therapies are not effective. It is more common in women under 40 and in certain genetic profiles, and tends to grow and spread faster, which is why early detection carries extra weight for this subtype.

HER2 Positive Breast Cancer

Roughly 15–20% of breast cancers are HER2 positive, according to oncology literature. While historically considered more aggressive, the development of HER2-targeted therapies has significantly improved outcomes for this subtype over the past two decades.

HER2 Negative Breast Cancer

HER2 negative cancers are far more common and are usually hormone receptor-positive, meaning they respond to hormone therapy. Treatment plans for HER2 negative cancer are typically built around ER/PR status instead.

How Is Breast Cancer Risk Actually Assessed?

Doctors don't rely on a single risk factor to predict breast cancer — they look at the full picture: age, family history, genetic testing results, breast density, reproductive history, and lifestyle.

Breast cancer risk is assessed using a combination of age, family history, genetic test results, and lifestyle factors. Tools like the Gail Model estimate a 5-year and lifetime risk percentage. No single factor determines risk on its own — assessment is always cumulative.

Why Early Detection Matters More Than “Cause”

Because no single cause can be eliminated with certainty, oncologists consistently emphasise early detection over cause-avoidance. Regular self-examination, clinical breast exams, and mammography from age 40 (or earlier with family history) remain the most reliable way to catch breast cancer at a treatable stage.

Where Does Ayurvedic Supportive Care Fit In?

This is where families often have the most questions — and where clear, compliant information matters most. Ayurvedic supportive care is not, and should never be presented as, a treatment, cure, or alternative to oncology care. Its realistic role is narrower and more specific: supporting a patient's strength, immunity, and quality of life alongside the treatment their oncologist has prescribed.

Ayurvedic supportive care refers to complementary wellness formulations used alongside — not instead of — conventional cancer treatment. It is used to support immunity, digestion, and general wellbeing during a patient's treatment journey. It does not replace surgery, chemotherapy, or radiation.

Body Revival: A Clinically Studied Supportive-Care Formulation

Health Reactive's flagship product, Body Revival, is an AYUSH-registered Ayurvedic liquid formulation manufactured under ISO and GMP certification. What sets it apart from most Ayurvedic wellness products on the market is that it has been evaluated in a CTRI-registered human clinical trial (CTRI/2023/11/059465), conducted at J.B. Roy State Ayurvedic Medical College, Kolkata — a level of clinical documentation that is uncommon among comparable supportive-care products in India.

To be clear: Body Revival is positioned strictly as a complementary supportive-care formulation intended to be used under medical guidance alongside a patient's prescribed oncology treatment. It is not marketed, and should never be represented, as a treatment or cure for cancer.

What “Supportive Care” Realistically Means for Patients and Families

In practice, supportive care is about helping a patient tolerate their treatment journey better — supporting appetite, energy, and general wellbeing during a demanding period — while every treatment decision continues to be made by the patient's oncology team. Families researching options should discuss any supportive-care product with their treating physician before starting it.

About the Author